Evidence map›Paper›PMID 25874774›Full record

ArticlePloS one2015

Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort.

Brittany L Mihelich, Joseph C Maranville, Rosalie Nolley, Donna M Peehl, Larisa Nonn

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Brittany L MihelichDepartment of Pathology, University of Illinois at Chicago, Chicago, IL, 60612, United States of America.
Joseph C MaranvilleClinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL, 60637, United States of America.
Rosalie NolleyDepartment of Urology, Stanford University, Palo Alto, CA, 94305, United States of America.
Donna M PeehlDepartment of Urology, Stanford University, Palo Alto, CA, 94305, United States of America.
Larisa NonnDepartment of Pathology, University of Illinois at Chicago, Chicago, IL, 60612, United States of America.
Stanford University · USUniversity of Illinois Chicago · USUniversity of Chicago · US

Funding

A Serum Marker for Aggressive Prostate CancerR01CA121460 · NCI · STANFORD UNIVERSITY · PI PEEHL, DONNA M. · 2006 to 2010
$2.2M
MiR-183-96-182 cluster, prostatic zinc homeostasis and carcinogenesisR01CA166588 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI NONN, LARISA · 2012 to 2016
$1.9M
NCI NIH HHS R01 CA121460NCI NIH HHS R01 CA166588
6 · The paper itself

Abstract

To reduce treatment of indolent prostate cancer (PCa), biomarkers are needed to improve identification of patients with a low-risk of having aggressive disease. Over-treatment of these patients occurs because of uncertainty in the aggressiveness of the entire tumor based on the biopsies, which do not accurately sample multifocal tumors. Circulating microRNAs (miRNAs) are stable serum markers and differential miRNA levels occur in men with PCa. The goal of this study was to identify circulating miRNAs that were associated with aggressive or indolent PCa. We measured circulating miRNAs in 150 patients prior to surgery and compared the miRNA levels to the pathology of the entire radical prostatectomy specimen. For this study we used an exceptionally well-characterized cohort of patients who had benign prostatic hyperplasia (BPH), low-grade or high-grade PCa. Low-grade was defined as patients with 100% Gleason grade 3 tumor as determined by step-wise sectioning. High-grade PCa patients had 30-90% Gleason grade 4+5 in the tumor. BPH patients had at least two biopsies negative for PCa. Twenty one miRNAs were selected for analysis. The miRNAs were quantified by RT-qPCR and analyzed by logistic regression. High levels of 14 miRNAs were exclusively present in the serum from patients with low-grade PCa or BPH, compared to men with high-grade PCa who had consistently low levels. The expression levels of the 14 miRNAs were combined into a "miR Score" which had a negative predictive value (NPV) of 0.939 to predict absence of high-grade PCa among PCa and BPH patients. Biochemical recurrence (BCR) was known for the PCa patients and a combined "miR Risk Score" accurately classified a subset of patients with low risk of BCR (NPV 0.941). In summary, measurement of serum miRNAs may have pre-surgical utility in combination with clinical risk calculators to identify patients with low risk of harboring aggressive PCa.

Indexed as

AgedAged, 80 and overCohort StudiesDisease-Free SurvivalHumansLogistic ModelsMaleMicroRNAsMiddle AgedNeoplasm GradingOdds RatioProstate-Specific AntigenProstatic HyperplasiaProstatic NeoplasmsReal-Time Polymerase Chain ReactionRetrospective StudiesMicroRNAsProstate-Specific Antigen

Identifiers

PMID25874774
PMCPMC4396984
OpenAlexW1974725571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.